EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access

Efficacy of the Cytokine Adsorption Therapy in Patients with Severe COVID-19-Associated Pneumonia: Lesson Learned from a Prospective Observational Study

Prit Kusirisin, Kajohnsak Noppakun, Konlawij Trongtrakul, Surachet Vongsanim, Yuttitham Suteeka, Vuddhidej Ophascharoensuk, Karn Pongsuwan, Phoom Narongkiatikhun, Theerakorn Theerakittikul, Nattayaporn Apaijai, Siriporn C Chattipakorn, Nipon Chattipakorn und 1 weitere

Blood Purification · 2024 · 53 (1) · 10-22

DOI: 10.1159/000534914 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Blood Purification, online erschienen am 02.11.2023. Verfasst von Prit Kusirisin und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand. Hauptthemen laut MEDLINE: COVID-19, Respiratory Distress Syndrome. Die Arbeit wurde bisher 10-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Severe COVID-19 pneumonia can activate a cytokine storm. Hemoperfusion can reduce pro-inflammatory cytokines in sepsis but is still debated in the COVID-19 setting. Thus, we sought to investigate the benefits of HA-330 cytokine adsorption through clinical and laboratory outcomes.

Methods

We conducted a single-center prospective observational study in adults with severe COVID-19 pneumonia admitted to the intensive care unit at Chiang Mai University Hospital (Chiang Mai, Thailand). Those with cytokine storms indicated by organ injury, including acute respiratory distress syndrome (ARDS), and high inflammatory markers were included. Patients treated with the HA-330 device were classified as a hemoperfusion group, while those without cytokine adsorption were classified as a control group. We compared the outcomes on day 7 after treatment and evaluated the factors associated with 60-day mortality.

Results

A total of 112 patients were enrolled. Thirty-eight patients received hemoperfusion, while 74 patients did not. Baseline cytokine storm parameters were comparable. In univariate analysis, there was an improvement in clinical and laboratory effects from hemoperfusion therapy. In multivariate analysis, APACHE II score, SOFA score, PaO2/FiO2, the number of hemoperfusion sessions, the amount of blood purified, high-sensitivity C-reactive protein, and IL-6 were associated with mortality. Using at least 3 sessions of hemoperfusion could mitigate, the 60-day mortality (adjusted odds ratio 0.25, 95% confidence interval: 0.03–0.33, p = 0.001). By categorizing the amount of blood treated into 3 groups of <1 L/kg, 1–2 L/kg, and ≥2 L/kg, there was a linear dose-response association with survival, which was better in the higher volume purified (mortality 60% vs. 33.3% vs. 0%, respectively, p = 0.015).

Conclusions

The early initiation of HA-330 hemoperfusion could improve the severity score and laboratory outcomes of COVID-19 ARDS. The optimal dose of at least three sessions or the amount of blood purified greater than 1 L/kg was associated with a reduction in 60-day mortality.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Respiratory Distress SyndromeAdultHumansAdsorptionCytokine Release SyndromeCytokines

Stichwörter der Autor:innen

Adsorption therapyCOVID-19HA-330HemoperfusionSevere acute respiratory syndrome coronavirus 2

Substanzen

Cytokines

Autor:innen und Institutionen

  • Division of Nephrology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
  • Excellence Center for Critical Care Nephrology, King Chulalongkorn Memorial Hospital, Bangkok, Thailand.
  • Center of Excellence in Critical Care Nephrology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
  • Cardiac Electrophysiology Research and Training Center, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
  • Center of Excellence in Cardiac Electrophysiology Research, Chiang Mai University, Chiang Mai, Thailand, Chiang Mai, Thailand.
  • Division of Pulmonary, Critical Care, and Allergy, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.

Zitieren

APA

Kusirisin, P., Noppakun, K., Trongtrakul, K., Vongsanim, S., Suteeka, Y., Ophascharoensuk, V., Pongsuwan, K., Narongkiatikhun, P., Theerakittikul, T., Apaijai, N., Chattipakorn, S. C., Chattipakorn, N., & Srisawat, N. (2024). Efficacy of the Cytokine Adsorption Therapy in Patients with Severe COVID-19-Associated Pneumonia: Lesson Learned from a Prospective Observational Study. Blood Purification, 53(1), 10-22. https://doi.org/10.1159/000534914

Vancouver

Kusirisin P, Noppakun K, Trongtrakul K, Vongsanim S, Suteeka Y, Ophascharoensuk V, et al. Efficacy of the Cytokine Adsorption Therapy in Patients with Severe COVID-19-Associated Pneumonia: Lesson Learned from a Prospective Observational Study. Blood Purification. 2024;53(1):10-22. doi:10.1159/000534914

BibTeX
@article{Kusirisin2024,
  author = {Kusirisin, Prit and Noppakun, Kajohnsak and Trongtrakul, Konlawij and Vongsanim, Surachet and Suteeka, Yuttitham and Ophascharoensuk, Vuddhidej and Pongsuwan, Karn and Narongkiatikhun, Phoom and Theerakittikul, Theerakorn and Apaijai, Nattayaporn and Chattipakorn, Siriporn C and Chattipakorn, Nipon and Srisawat, Nattachai},
  title = {Efficacy of the Cytokine Adsorption Therapy in Patients with Severe COVID-19-Associated Pneumonia: Lesson Learned from a Prospective Observational Study},
  journal = {Blood Purification},
  year = {2024},
  volume = {53},
  number = {1},
  pages = {10--22},
  doi = {10.1159/000534914}
}
Kostenlos starten →